Skip to content

Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism

Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07143539
Acronym
RehabPE
Enrollment
160
Registered
2025-08-27
Start date
2025-12-17
Completion date
2028-06-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Depression, Dyspnea, Exercise Therapy, Exercise Tolerance, Functional Status, Humans, Pulmonary Embolism (Diagnosis), Quality of Life (QOL), Rehabilitation Exercise, Venous Thromboembolism (VTE)

Keywords

pulmonary embolism, deep vein thrombosis, excercise-based rehabilitation, post-PE syndrome, health-related quality of life, anxiety, depression, dyspnea, impact of early excercise-based rehabilitation

Brief summary

Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects. The study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management. Over 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work / usual daily activities will be monitored and compared between groups.

Interventions

Participants in the intervention group will receive a patient-tailored early (i.e., within 4 weeks of PE diagnosis) EBR program, comprising 16-18 sessions of supervised aerobic exercise and resistance/strength training at local outpatient rehabilitation centers, along with 2 PE-related educational sessions at 2 and 6 weeks of rehabilitation. Participants will receive comprehensive information on the purpose of EBR and each of its components, reassurance on its safety, and education on self-monitoring. Furthermore, physiotherapists will tailor the training based on specific capabilities, focusing on areas of weakness.

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Study staff, blinded to participants' study group allocation, will conduct follow-up visit and assessments.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥18 years 2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days 3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission 4. Written informed consent

Exclusion criteria

1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension) 2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment) 3. Recently completed (i.e., \<6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication 4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy) 5. Contraindication to anticoagulation 6. Life expectancy \<1 year based on the treating physician's clinical judgement 7. Known pregnancy 8. Inability to speak German or French 9. Participation in another study that prohibits concurrent participation in RehabPE 10. Unable to provide informed consent (e.g., due to dementia) 11. Unwilling to provide informed consent 12. Prior enrollment in this study

Design outcomes

Primary

MeasureTime frameDescription
Change in generic health-related quality of life (Physical Component Summary score; SF-36)From baseline to day 90 after randomizationChange from baseline to day 90 after randomization in generic healt-related quality of life (HRQoL) assessed by the PCS score of the self-completed SF-36 questionnaire. The SF-36 consists of 36 questions measuring 8 domains (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health) and assesses generic HRQoL during the previous 30 days. The PCS score is obtained from all 8 domains and ranges from 0 to 100.

Secondary

MeasureTime frameDescription
Change in generic health-related quality of life (Physical Component Summary score; SF-36)From baseline to day 180 after randomizationChange from baseline to day 180 after randomization in the SF-36 Physical Component Summary score, ranging from 0 to 100 with higher scores indicating better HRQoL.
Change in generic health-related quality of life (Mental Component Summary score; SF-36)From baseline to day 90 and to day 180 after randomizationChanges from baseline to day 90 and to day 180 after randomization in the SF-36 Mental Component Summary score, ranging from 0 to 100 with higher scores indicating better HRQoL.
Change in PE-specific health-related quality of life (PEmb-QoL)From baseline to day 90 and to day 180 after randomizationChange from baseline to day 90 and to day 180 after randomization in PE-specific health-realted quality of life assessed by the self-completed PEmb-QoL questionnaire, which comprises 9 questions covering 6 domains, with scores ranging from 0 to 100. Total scores will be calculated based on the average of scores of all 6 domains.
Change in physical exercise capacity (6 minute walking test)From baseline to day 90 and to day 180 after randomizationChange in physical exercise capacity from baseline to day 90 and to day 180 after randomization will be measured by the 6 minute walking test (6MWT). Participants will be asked to walk as far as possible in 6 minutes along a flat corridor of at least 30 mesters under supervision, and the distance in meters will determine the 6MWD.
Change in functional status (Post-VTE Functional Status)From baseline to day 90 and to day 180 after randomizationChange in functional status will be assessed by the Post-VTE Functional Status scale, where patients will grade their functional status on a scale ranging from 0 (no limitations due to VTE symptoms) to 4 (depending on assistance in activities of daily living due to VTE symptoms).
Time to return to work (workers) or usual activities of daily living (non-workers)For the duration of the study: 180 daysTime (days) to return to work in workers or to usual activities of daily living in non-workers will be obtained based on information from patient interviews.
Change in dyspneaFrom baseline to day 90 and to day 180 after randomizationDyspnea will be measured based on information from patient interviews, using the NYHA classification, ranging from 1 (no limitation of physical activity due to shortness of breath) to 4 (unable to carry on any physical activity without shortness of breath).
Change in symptoms of anxiety (GAD-7)From baseline to day 90 and to day 180 after randomizationChange in symptoms of anxiety will be assessed by the self-completed General Anxiety Disorder 7 (GAD-7) ranging from 0 to 21 points.
Change in symptoms of depression (PHQ-9)From baseline to day 90 and to day 180 after randomizationChange in symptoms of depression will be assessed by the self-completed Patient Health Questionnaire 9 (PHQ-9), ranging from 0 to 27 points.

Countries

Switzerland

Contacts

CONTACTTobias Tritschler, Prof. Dr. med., MSc
tobias.tritschler@insel.ch+41 (0)31 632 01 46
PRINCIPAL_INVESTIGATORTobias Tritschler, Prof. Dr. med., MSc

Inselspital, Universitätsspital Bern

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026